Astragaloside Ⅳ attenuates renal tubulointerstitial fibrosis by inhibiting p38 MAPK signaling

徐维佳,邵兴华,徐晓萍,姚菊芳,王琴,张敏芳,王玲,田磊,牟姗

DOI: https://doi.org/10.3760/cma.j.issn.1001-7097.2014.10.008

2014-01-01

Abstract:Objective To investigate the effect of astragaloside Ⅳ (AS-Ⅳ) on renal tubulointerstitial fibrosis and its regulation on p38 MAPK signaling.Methods In vivo,UUO model with renal tubulointerstitial injury was constructed.Mice in AS-Ⅳ group were orally administrated AS-Ⅳ 20 mg· kg 1 · d-1 for 7 days after operation,and mice in other groups were administrated the equal volume vehicle.Bilateral kidneys were collected in 7 and 14 days after operation.Transverse kidney slices were stained with Masson trichrome to evaluate the severity of renal tubule injury.In vitro,normal human renal tubular epithelial cells (HK-2) were stimulated with recombinant TGF-β1 (10 ng/ml) and simultaneously treated with different concentrations of AS-Ⅳ (0,50,100,200 μg/ml) for 24 h.SB203580 (10 μmol/L) was also ultilized to pre-treat HK-2 cells for 1 h to inhibit phosphorylation of p38 MAPK signaling.The expression of FN,Col Ⅳ,and α-SMA were investigated by western blotting and real-time PCR.The expression of p-p38 MAPKs were also observed by Western Blotting.Results Astragaloside Ⅳ morphologically ameliorated renal tubulointerstitial fibrosis.The proteins and mRNA expression of FN,Col Ⅳ,α-SMA,and TGF-β1 were also increased significantly in UUO kidney tissues (all P ＜ 0.05),which could be reversed by AS-Ⅳ administration (all P ＜ 0.05).In vitro,the expression of FN,Col Ⅳ,and α-SMA were up-regulated by TGF-β1 after stimulating for 24 h (all P＜0.05),which were decreased by AS-Ⅳ.The inhibition effect on FN and α-SMA were similar between AS-Ⅳ and MAPK inhibitor SB203580.AS-Ⅳ inhibited p-p38 MAPK signals both in vivo and in vitro.Conclusions AS-Ⅳ could attenuate renal tubulointerstitial fibrosis induced by UUO and TGF-β1 through reducing FN、Col Ⅳ、α-SMA expression in renal tubular cells.The mechanism of AS-Ⅳ protective effect might be associated with inhibition of p38 MAPK phosphorylation.